Y-mAbs Therapeutics (NASDAQ:YMAB) Shares Gap Up to $12.07

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)’s share price gapped up before the market opened on Friday . The stock had previously closed at $12.07, but opened at $12.54. Y-mAbs Therapeutics shares last traded at $12.98, with a volume of 46,636 shares traded.

Analysts Set New Price Targets

A number of research analysts recently weighed in on YMAB shares. HC Wainwright lifted their target price on shares of Y-mAbs Therapeutics from $21.00 to $22.00 and gave the company a “buy” rating in a research note on Monday, May 13th. Truist Financial started coverage on shares of Y-mAbs Therapeutics in a research note on Friday, June 28th. They set a “buy” rating and a $21.00 target price on the stock. Two investment analysts have rated the stock with a sell rating and five have issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $17.86.

Y-mAbs Therapeutics Trading Up 1.7 %

The firm has a market cap of $538.85 million, a PE ratio of -24.63 and a beta of 0.66. The firm’s 50 day simple moving average is $12.35 and its 200 day simple moving average is $13.09.

Y-mAbs Therapeutics (NASDAQ:YMAB) last released its quarterly earnings data on Tuesday, May 7th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.03). The company had revenue of $19.93 million during the quarter, compared to analysts’ expectations of $22.06 million. Y-mAbs Therapeutics had a negative net margin of 25.64% and a negative return on equity of 21.40%. As a group, equities research analysts predict that Y-mAbs Therapeutics, Inc. will post -0.52 earnings per share for the current fiscal year.

Insider Buying and Selling at Y-mAbs Therapeutics

In other Y-mAbs Therapeutics news, insider Thomas Gad sold 35,000 shares of the business’s stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $12.03, for a total value of $421,050.00. Following the completion of the sale, the insider now directly owns 197,681 shares of the company’s stock, valued at approximately $2,378,102.43. The transaction was disclosed in a filing with the SEC, which is available through this link. In other news, CFO Bo Kruse sold 31,371 shares of the company’s stock in a transaction that occurred on Friday, May 31st. The shares were sold at an average price of $12.07, for a total value of $378,647.97. Following the completion of the sale, the chief financial officer now owns 210,877 shares of the company’s stock, valued at approximately $2,545,285.39. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Thomas Gad sold 35,000 shares of the company’s stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $12.03, for a total transaction of $421,050.00. Following the completion of the sale, the insider now directly owns 197,681 shares of the company’s stock, valued at approximately $2,378,102.43. The disclosure for this sale can be found here. Insiders sold a total of 99,444 shares of company stock valued at $1,203,925 in the last three months. Company insiders own 21.50% of the company’s stock.

Institutional Investors Weigh In On Y-mAbs Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Los Angeles Capital Management LLC lifted its position in Y-mAbs Therapeutics by 17.3% during the fourth quarter. Los Angeles Capital Management LLC now owns 356,530 shares of the company’s stock valued at $2,432,000 after acquiring an additional 52,610 shares during the last quarter. Campbell & CO Investment Adviser LLC purchased a new stake in Y-mAbs Therapeutics during the fourth quarter valued at approximately $562,000. Federated Hermes Inc. lifted its position in Y-mAbs Therapeutics by 4,708.0% during the fourth quarter. Federated Hermes Inc. now owns 44,474 shares of the company’s stock valued at $303,000 after acquiring an additional 43,549 shares during the last quarter. Sapient Capital LLC purchased a new stake in Y-mAbs Therapeutics during the fourth quarter valued at approximately $298,000. Finally, Boston Partners purchased a new stake in Y-mAbs Therapeutics during the first quarter valued at approximately $556,000. Hedge funds and other institutional investors own 70.85% of the company’s stock.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.